CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
SpaceOAR Treatmentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05407714
NCT05407714N/ACompleted

A Real Word Study to Evaluate the Safety and Performance of SpaceOAR System When Used to Create Space Between the Rectum and Prostate in Men Undergoing Radiotherapy for Localized T1-T2 Prostate Cancer in China

Boston Scientific Corporation·interventional·Posted Jun 7, 2022·Updated Oct 27, 2025

In Brief

A clinical study evaluating SpaceOAR Treatment for Localized T1-T2 Prostate Cancer. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This study aims to evaluate the safety and performance of SpaceOAR System when it is used to create space between the rectum and prostate in men undergoing radiotherapy for localized T1-T2 prostate cancer in China via collecting the real word data of SpaceOAR System used, to generate local clinical evidence on Chinese patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJun 7, 2022
Enrollment StartAug 18, 2022
Primary CompletionJun 12, 2023
Study CompletionJul 6, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.1 years ago

Interventions

SpaceOAR Treatmentdevice

SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR System to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR System is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.